Dr. Gur Levy, Respiratory Medical Expert at GSK, said, "We have been pioneering efforts for decades to develop new ...

Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on December 11.Pick the ...

GlaxoSmithKline (GSK)’s B7-H3-targeted antibody-drug conjugate (ADC), GSK’227 has gained priority medicines (PRIME) ...

The $14.75-per-share deal will add P2X3 antagonist camlipixant to GSK’s respiratory pipeline, a drug which the UK-headquartered big pharma reckons could be ready for launch in 2026, although it ...

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

GSK said on Thursday it had expanded its agreement with China's largest vaccine company Zhifei to explore a potential ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...

China's Zhifei will pay GSK about 2.3 billion pounds ($2.9 billion) for the exclusive rights to distribute GSK's shingles ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for ...

Under the revised agreement, the two have taken their RSV commitment a step forward as Zhifei agrees to engage exclusively ...

The partnership focuses on the discovery and validation of new therapeutics that target fibrotic diseases and osteoarthritis. Credit: murat photographer/Shutterstock ...